Most adrenal nodules are harmless growths that will never cause you a problem. When CT scans of the abdomen are reviewed systematically, roughly 5% of patients turn out to have an adrenal mass they never knew about, and the vast majority of those are benign adenomas that produce no excess hormones and pose no cancer risk.1PubMed. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy But “probably fine” and “definitely fine” are not the same thing, and what happens next after the finding matters. The evaluation is straightforward, usually non-invasive, and designed to sort out the small fraction of nodules that do need attention.
Why Adrenal Nodules Show Up So Often
Adrenal nodules are one of the most common incidental findings in modern medicine. They almost always turn up on imaging ordered for something else entirely, such as a CT scan after a car accident, an abdominal scan for kidney stones, or staging workup for an unrelated condition. The term doctors use is “adrenal incidentaloma,” which simply means an adrenal mass found by accident rather than because someone went looking for it. One review of abdominal CT scans found adrenal abnormalities in about 12% of scans when radiologists specifically re-examined them for adrenal findings, though only about 7% had been flagged in the original reports.2PubMed Central. An Adrenal Incidentaloma: How Often Is It Detected and What Are the Consequences? The discrepancy highlights that many small adrenal nodules go unreported because they are so clearly benign on imaging that radiologists do not always mention them.
The prevalence increases with age. If you are in your fifties or older and get any kind of abdominal scan, the odds of an incidental adrenal finding are higher than most people expect. This is not a sign that something has gone wrong with your health. The adrenal glands, like many organs, develop small benign growths over the course of a lifetime. The challenge is figuring out which of these findings deserve further evaluation and which can be safely left alone.
What Makes a Nodule Look Benign on Imaging
The first and most important clue comes from the CT scan that found the nodule in the first place. Doctors look at two main features: how dense the nodule appears (measured in Hounsfield units, or HU) and how large it is. Benign adrenal adenomas tend to be rich in fat, which makes them appear less dense on a scan. A nodule measuring 10 HU or less on an unenhanced CT is very likely to be a benign adenoma. One analysis of the CT literature found that using a threshold of 10 HU correctly identified benign lesions with a sensitivity around 71% and specificity around 98%.3PubMed. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature In practice, this means that if your nodule is small and has low density, it is almost certainly a plain adenoma, and your doctor may not need to order much more testing.
When the density is higher than 10 HU, the picture is less clear-cut. Some benign adenomas do not contain much fat and therefore look denser on the initial scan. In these cases, doctors may order a “washout” CT, which involves giving contrast dye and then scanning again after a delay to see how quickly the dye leaves the nodule. Benign adenomas tend to wash out the contrast quickly, while malignant lesions hold onto it. The technique is widely used, though it adds cost and radiation exposure.4PubMed Central. Distinguishing benign from malignant adrenal masses One cost-effectiveness study found that using a single unenhanced CT at the time of diagnosis was actually the most cost-effective approach for ruling out adrenal cancer, rather than routinely adding washout CT for every patient.5PubMed. Cost-Effectiveness of Follow-Up Imaging for Incidental Adrenal Nodules to Rule Out Adrenocortical Carcinoma
It is also worth knowing that CT density measurements are not perfectly standardized across machines. Different scanners and protocols can produce somewhat different readings for the same nodule, which makes rigid cutoffs less reliable than they might seem.6PubMed. CT density measurements for characterization of adrenal tumors ex vivo: variability among three CT scanners Your doctor interprets the number in context, not as an absolute verdict.
When MRI Adds Useful Information
If a CT scan leaves the diagnosis uncertain, MRI can help, particularly a technique called chemical shift imaging. This method exploits the fact that fat and water behave differently in a magnetic field. Because benign adenomas contain microscopic fat droplets scattered among their cells, they lose signal on a specific MRI sequence in a way that malignant tumors typically do not. Chemical shift MRI is considered a reliable tool for evaluating adrenal lesions that remain unclear after CT.7PubMed. Chemical Shift MR Imaging of the Adrenal Gland: Principles, Pitfalls, and Applications
A multi-institutional study found that adrenal nodules showing even patchy microscopic fat on chemical shift MRI had a high likelihood of being benign, especially in patients without a prior cancer diagnosis. The picture was somewhat less reassuring in patients who had a known malignancy, particularly cancers that can themselves contain fat or where an unusual “collision tumor” could mimic a benign pattern.8PubMed. Prevalence of Malignancy in Adrenal Nodules With Heterogeneous Microscopic Fat On Chemical-Shift MRI: A Multiinstitutional Study Combined with newer spectroscopy techniques that measure the chemical makeup of the tissue, MRI accuracy for distinguishing adenomas from other lesions continues to improve.9PubMed Central. The value of signal intensity on T1-weighted chemical shift magnetic resonance imaging combined with proton magnetic resonance spectroscopy for the diagnosis of adrenal adenomas
The Hormone Question
Even when a nodule looks completely benign on imaging, your doctor will usually check whether it is producing excess hormones. The adrenal glands make cortisol, aldosterone, and adrenaline-related hormones, and a nodule can quietly overproduce any of these without causing obvious symptoms at first. This “silent” hormone overproduction is actually the more common clinical concern with adrenal incidentalomas, far more common than malignancy.
Cortisol Overproduction
Up to about 20% of people with adrenal incidentalomas have some degree of abnormal cortisol production, a condition sometimes called subclinical Cushing’s syndrome.10PubMed. Subclinical Cushing’s syndrome in adrenal incidentalomas “Subclinical” means you do not develop the classic signs of full-blown Cushing’s, such as a round “moon face” or purple stretch marks. But the subtle cortisol excess is not necessarily harmless. A study comparing patients with subclinical Cushing’s to matched controls found significantly higher blood pressure, blood sugar, cholesterol, and markers of insulin resistance. Over half had lipid abnormalities, and about a third had type 2 diabetes or impaired glucose tolerance. Atherosclerotic plaques in the carotid arteries were also much more common.11The Journal of Clinical Endocrinology & Metabolism. Patients with Subclinical Cushing’s Syndrome due to Adrenal Adenoma Have Increased Cardiovascular Risk
The screening test is simple: you take a low dose of dexamethasone at bedtime, and your cortisol is measured the next morning. In a normal response, cortisol drops. If it does not suppress adequately, further evaluation is needed. This is not a scary test, just a blood draw, and it picks up a problem that might otherwise quietly increase your cardiovascular risk over years.
Adrenaline-Producing Tumors
Pheochromocytomas are rare tumors that make excess adrenaline and related hormones, causing episodes of high blood pressure, rapid heartbeat, sweating, and headaches. They account for a small fraction of adrenal incidentalomas, but missing one can be dangerous, especially if surgery is ever needed for another reason. The best screening test is plasma metanephrines (breakdown products of adrenaline). One study found plasma normetanephrine had a sensitivity above 90% and specificity above 95% for detecting pheochromocytoma.12European Journal of Endocrinology. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass A reassuring finding from a Mayo Clinic analysis is that if the nodule measures under 10 HU on unenhanced CT, the chance of pheochromocytoma is so low that biochemical testing for it may not even be necessary.13PubMed Central. Not all adrenal incidentalomas require biochemical testing to exclude pheochromocytoma: Mayo clinic experience and a meta-analysis
Aldosterone Overproduction
If you have high blood pressure, particularly if it is hard to control with medication, your doctor should consider whether the nodule is producing excess aldosterone. Primary aldosteronism is a treatable cause of hypertension, and the screening test is a ratio of aldosterone to renin in the blood. One case report illustrates an important pitfall: a 65-year-old man with resistant hypertension had a visible nodule on one adrenal gland, but specialized vein sampling showed the excess aldosterone was actually coming from the opposite gland.14PubMed Central. Resistant hypertension with adrenal nodule: are we removing the right gland? The visible nodule was an innocent bystander. This is why endocrinologists do not assume that what you see on imaging is what is causing the hormonal problem. High systolic blood pressure and a history of stroke are among the factors that increase the probability of unilateral aldosterone overproduction when a nodule is present.15PubMed Central. Screening for unilateral aldosteronism should be combined with the maximum systolic blood pressure, history of stroke and typical nodules
Size and the Risk of Cancer
Nodule size is one of the strongest predictors of whether an adrenal mass could be malignant. Most guidelines use 4 cm as the key threshold. According to the American Association of Endocrine Surgeons, the prevalence of adrenocortical carcinoma (a rare primary adrenal cancer) is under 0.5% for nodules smaller than 4 cm, about 5% for those between 4 and 6 cm, and up to 35% for those larger than 6 cm.16JAMA Surgery. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary The same guidelines recommend considering primary adrenal malignancy in any nodule over 4 cm, any nodule denser than 20 HU on unenhanced CT, or any adrenal mass in a patient under 18.
These cutoffs are not absolute, though, and there is genuine disagreement among guidelines about where exactly to draw the line. Size recommendations for when to proceed to surgery range from under 4 cm up to 12 cm depending on the guideline and the clinical context.17PubMed Central. Adrenal Incidentaloma Controversial Size Recommendations One helpful nuance comes from a single-center study showing that when a tumor had low density on CT (under 40 HU), the risk of adrenocortical carcinoma was zero regardless of size. In other words, density and size together are more informative than either measure alone.18PubMed. Tumour size in adrenal tumours: its importance in the indication of adrenalectomy and in surgical outcomes
If You Have a History of Cancer
The calculus changes significantly if you have been diagnosed with cancer in the past. In the general population without known malignancy, an adrenal nodule is overwhelmingly likely to be benign. But in cancer patients, the adrenal glands are a known destination for metastases. A recent study of 420 cancer patients with adrenal nodules found an overall metastatic rate of about 16%. The risk was highest in patients with melanoma (50% of adrenal nodules were metastatic) and lung cancer (about a third). Larger nodules and the presence of metastatic disease elsewhere in the body both increased the odds substantially.19PubMed. Assessing the malignancy rate of adrenal nodules in patients with a history of cancer: factors associated with adrenal metastases
Even so, not every adrenal nodule in a cancer patient is a metastasis. A surgical series found that about half of adrenal masses in patients with a known extra-adrenal malignancy turned out to be something other than metastases, including ordinary adenomas, pheochromocytomas, and even primary adrenal cancers.20PubMed. Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy This is why imaging characteristics and sometimes biopsy remain important rather than assuming the worst.
The Limited Role of Biopsy
Adrenal biopsy is not part of the routine workup for most incidentalomas. It is reserved for specific situations, primarily when a cancer patient has an adrenal mass that imaging alone cannot characterize and the result would change treatment. A meta-analysis of over 2,000 adrenal biopsies found a non-diagnostic rate of about 9% and a complication rate around 2.5%.21European Journal of Endocrinology. The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis The complications are mostly bleeding-related. In cases of suspected adrenocortical carcinoma specifically, biopsy performs poorly, with a maximum sensitivity of about 70% and a complication rate of at least 11%.22European Journal of Endocrinology. Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome And critically, a pheochromocytoma must always be ruled out biochemically before biopsy, because sticking a needle into one of those tumors can trigger a dangerous surge in adrenaline.
What Follow-Up Looks Like
If your nodule is small, low-density, and hormonally inactive, you may not need extensive follow-up at all. The European Society of Endocrinology guidelines support the view that patients with clearly benign-looking lesions under 4 cm and no hormonal overproduction can skip ongoing surveillance imaging, though this recommendation is still awaiting confirmation from larger prospective studies, especially for younger patients.23PubMed Central. Is Follow-up of Adrenal Incidentalomas Always Mandatory?
For nodules that warrant monitoring, the track record is reassuring. A 10-year longitudinal study of non-functioning adrenal incidentalomas found that about 9% showed meaningful growth over the follow-up period, but none of the growing nodules developed imaging features suggestive of cancer. All retained the appearance of benign adenomas.24Endocrine Connections. Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study Another long-term study estimated that the cumulative risk of a nodule enlarging was about 18% over five years and 23% over ten years, but none of those enlarged masses turned out to be malignant. The risk of developing new hormonal overproduction was lower, at roughly 10% over five years.25The Journal of Clinical Endocrinology & Metabolism. Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas These numbers mean that even when a nodule grows, cancer is not the typical explanation; it is usually just the adenoma slowly getting bigger.
When Surgery Is Recommended
Surgery becomes the recommendation when a nodule is producing clinically significant hormones (confirmed pheochromocytoma, primary aldosteronism causing resistant hypertension, or cortisol excess contributing to worsening metabolic disease), when imaging suggests malignancy, or when the nodule is large enough to raise concern. The standard approach is laparoscopic adrenalectomy, a minimally invasive procedure done through small incisions. In a large series of 462 patients, there were no deaths and the overall complication rate was about 12%, mostly minor. Conversion from laparoscopic to open surgery was the strongest predictor of complications.26British Journal of Surgery. Risk factors for conversion and complications after unilateral laparoscopic adrenalectomy A separate study of over 650 laparoscopic adrenalectomies found a significant complication rate of about 8%, with tumors 6 cm or larger, diabetes, and pheochromocytoma each independently increasing the risk.27JAMA Surgery. Risk Factors Associated With Perioperative Complications and Prolonged Length of Stay After Laparoscopic Adrenalectomy Overall, adrenalectomy for the right indication is a well-tolerated operation with low mortality.
Bilateral Nodules
Finding nodules on both adrenal glands understandably raises more alarm, but the causes are not dramatically different from unilateral findings. In one post-hoc analysis of patients with bilateral nodules who completed full endocrine testing, about half turned out to be non-functioning adenomas, about 40% had hormonal overproduction (either cortisol or aldosterone), and the remaining 12% were caused by tuberculosis, an infectious etiology that was significantly more common in bilateral cases than unilateral ones.28PubMed. Characteristics and etiological profile of bilateral adrenal nodules: A Post-hoc analysis Bilateral incidentalomas also appear to be more likely to show abnormal cortisol responses. In a prospective study, only a third of patients with bilateral incidentalomas suppressed their cortisol normally on a dexamethasone test, compared to about two-thirds of those with a unilateral nodule.29PubMed. Correlation Between Size and Function of Unilateral and Bilateral Adrenocortical Nodules: An Observational Study The takeaway is that bilateral findings deserve thorough hormonal evaluation but are not inherently more likely to be cancer.
Children and Young Adults
Adrenal incidentalomas are extremely rare in children, and that rarity itself is the concern. When an adrenal mass does turn up incidentally in a child or adolescent, the risk of malignancy is significantly higher than in adults. European endocrinology guidelines recommend urgent assessment of any adrenal mass found in a pediatric patient, rather than the watch-and-wait approach that can be appropriate for a small, benign-appearing nodule in an older adult.30Journal of Pediatric Surgery Case Reports. Pediatric adrenal incidentaloma The same heightened caution applies to people under 18 according to the American Association of Endocrine Surgeons guidelines, which flag any adrenal mass in this age group as requiring consideration for malignancy.16JAMA Surgery. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary
Artificial Intelligence and the Future of Diagnosis
One of the more promising developments in adrenal nodule management is the use of machine learning and radiomics, where software analyzes imaging features that are invisible to the human eye. A systematic review of studies in this area found that AI models have been developed for several tasks: distinguishing benign from malignant adrenal lesions, classifying nodule subtypes, and even identifying whether an incidentaloma is secreting excess hormones, a determination that currently requires blood tests or invasive vein sampling. All of the models reviewed achieved diagnostic accuracy above an AUC of 0.80, and some outperformed conventional radiologist assessment.31PubMed Central. Artificial intelligence and radiomics applications in adrenal lesions: a systematic review A separate study using a combination of deep learning and radiomic features from ultrasound imaging achieved an AUC of 0.85 for differentiating adrenal metastases from adenomas.32PubMed Central. Differentiation of adrenal metastases and adenomas based on clinical characteristics, deep learning features, and radiomics features derived from ultrasound imaging These tools are still in early stages, limited by small study sizes and the need for validation across different hospitals and scanner types. But they point toward a future where imaging alone could tell doctors not just whether a nodule looks benign, but whether it is hormonally active, reducing the need for some blood tests and invasive procedures.